Merck, Daiichi repeat early success in small cell lung cancer with updated ADC data

Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. The drugmaker’s Daiichi Sankyo-partnered antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd) showed promise in the setting, offering encouragement as a late-stage trial progresses.